<DOC>
	<DOCNO>NCT01507389</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate liraglutide subject mild , moderate severe degree hepatic impairment compare subject normal hepatic function .</brief_summary>
	<brief_title>Safety Liraglutide Subjects With Liver Impairment Subjects With Normal Liver Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects normal hepatic function liver parameter within normal range Subjects stable hepatic impairment classify ChildPugh grade A , B C Body Mass Index 18.540.0 kg/m^2 ( inclusive ) Known suspect allergy trial product relate product Liver transplant subject Cardiac problem Uncontrolled treated/untreated hypertension Signs acute liver insufficiency Positive HIV ( human immunodeficiency virus ) 1+2 antibody Cancer clinically significant disease disorder except condition associate hepatic impairment Impaired renal function Smoking 10 cigarette per day , equivalent tobacco product Habitual excessive consumption methylxanthinecontaining beverage food ( coffee , tea , soft drink cola , chocolate ) judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>